reason report
bottom line hang regard posit view
basic reflect view aducanumab
approv base current data set admit
manag commentari made us increment
concern disappoint wait anoth
quarter get answer updat model print
minor ep bump reiter outperform rate
pt
simpl commun issu file interpret
bear believ someth materi chang regard
fda view program current data
set engage/emerg enough approv previou
manag comment point minor item left complet
file earli bla file delay roughli
two quarter head agenc chang
could issu believ disappoint dian-tu result
chang fda percept amyloid hypothesi
investor indic compani spent less build commerci
infrastructur launch know may
problem ultim bear believ kick regard
file time manag way slowli introduc invest
commun need addit confirmatori pivot studi
bull support manag view delay
commun issu manag indic process
taken longer expect even exclud delay caus
sound easi put packag togeth
bla complex tough predict time
new materi question fda noth come
chang posit view dataset plan fda
meet begin someth chang
commun new inform invest commun
realli commun issu would nice
view manag mea culpa admit er
optimist file timelin also reiter noth
fundament chang fda interact data analysi
think could help mitig investor reaction today
expect bla file april lost
product current work-at-hom environ would
mostli made compani put addit resourc
project disappoint delay hard believ
compani inform svb leerink llc research
revenu mm non-gaap dilut ep
sotp analysi forecast cash
flow discount
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
pleas refer page import disclosur price chart analyst certif
someth chang regard compani interact
fda howev alway unusu situat
manag sound pretti convinc fda view
chang regard data mayb chang
increment meaning enough delay materi
overal end-gam approv process
takeaway confer call regard
aducanumab open bla alreadi start submit modul
pre-bla meet schedul summer plu addit
formal meet given roll bla fda
work close compani data set still
expect quick turnaround time approv around end year
complet bla submiss regard product
sale manag indic base busi demand
resili sale pull
environ clear whether offset neg
impact sale come and/or given unusu situat
regard pandem continu mitig
risk identifi opportun across suppli chain clinic studi
base busi via adjust oper acceler digit
engag launch consortium multipl partner
build share biobank regard pipelin updat
manag indic updat clinic trial principl base
fda guidelin ensur safeti data integr
note major remain mid-to-late-stag pipelin
asset remain track data readout end
provid guidanc exact time mileston
nearli question call center around file
delay overal compani note hold pre-bla meet
type meet natur cours file like particularli
data set aducanumab larg patient
whole process collabor fda sinc first
type meet last june compani reiter noth
data interact chang level confid
potenti approv aducanumab manag also note
employe got sick delay process
also mention priorit qualiti speed bla file
ensur data element robust possibl submiss
key modul roll bla includ manufactur non-clin data
mostli complet clinic data regard file japan
europ manag indic alreadi start engag
ou regulatori agenc process still earli stage
alreadi initi embark re-dos studi aducanumab
patient dose march manag believ
studi would requir bla file manag expect
adequ suppli support commerci launch new
manufactur plant oper year-end suppli
aducanumab
us sale yoy basic line consensu
us sale benefit covid environ pull procedur
volum forward surpris given recent medacorp kol
treatment center chose administ patient ahead schedul march
normal would dose anticip peak
infect april expect sale pull forward neg impact
addit risk delay dose height on-going
pandem still think lost sale made kol
indic patient dose delay would return patient
origin inject schedul preserv best efficaci spinraza
us patient grew qtq medacorp kol
interact appear adult popul continu becom
increment import growth opportun seem novarti
zolgensma take major newli born/babi
ou sale split differ consensu
forecast sale benefit covid
devot studi initi evalu whether higher dose spinraza
drive dose-depend better efficaci
us tecfidera sale yoy higher vs estim
higher consensu
us channel inventori declin follow increas
us vumer sale notabl consensu
bearish product note sale still
forecast manag sound optimist regard progress obtain
access reimburs forecast remain consensu
vs consensu vs consensu
vs consensu
manag expect major impact tecfidera/vumer us sale
product mostli ship via mail order
manag reiter confid tecfidera patent upheld
given back three rule includ posit ipr decis
februari
ou tecfidera sale yoy higher vs estim
higher consensu
manag believ ou sale benefit net benefit
prior year
us tysabri sale yoy higher vs estim
higher consensu
us channel inventori increas follow increas
ou tysabri sale yoy higher vs estim
higher consensu signific beat explain
manag believ ou sale benefit net benefit
manag also indic ou sale help due price
adjust itali relat prior period
manag acknowledg infus neg impact
environ continu work enabl home infus tysabri
total biosimilar sale yoy continu show strength
higher vs estim higher consensu
manag believ net benefit due
manag estim patient use biosimilar europ
benepali remain prescrib biosimilar enbrel across five major eu
pipelin bd outlook
natalizumab focal epilepsi studi read neg program
initi phase studi dapirolizumab pegol system lupu
erythematosu sle paus part effort limit trial evalu
molecul suppress immun system
compani confirm file ind sporad al
file new formul im plegridi us/eu
manag believ remain pipelin readout still
occur end
manag reiter commentari regard capit deploy believ
still financi flexibl pursu bd opportun
continu activ bd front guidelin thought
invest short- long-term growth
invest thesi four-fold
believ aducanumab better chanc get approv earli
alzheim diseas ad becom signific product peak sale
yet stock reflect po
valuat alreadi reflect signific spinraza declin due new competit
assum best case scenario tecfidera gener entri
base favor ipr board decis
durabl base busi profit stream multipl sclerosi ms
franchis royalti biosimilar remain underappreci provid
pipelin get minim attent valu attribut thu good news
portfolio drive upsid valuat
pt base sum-of-the-part sotp analysi forecast cash flow
discount rate
risk valuat
risk invest thesi
aducanumab approv fda
new safeti signal aducanumab detect practic hinder commerci
base busi deterior wors expect
tecfidera gener entri happen
spinraza declin even faster forecast
early-stag pipelin product fail late-stag studi
sclerosistot tecfidera franchis growth growth tecfidera growth interferon franchis growth growth growth growth provid growth provid growth provid growth provid multipl sclerosi growth growth multipl growth biogen inc
sale growth provid growth provid growth provid growth rate growth growth biosimilar growth rate growth provid sale growth growth excl ad sale eisai growth growth provid biogen inc
 oper activitiesnet incom oper asset liabil use oper invest activitiescapit market intangibles/aquir busi ionis/samsung consider fumapharma invest use invest financ activitiesnet chang distribut non-control consider incl payment use financ equival begin equival end inc
 balanc sheet asset receiv current current equip tax stockhold equitycurr liabilitiesaccount payabl accru tax debt current portion lt expens current term tax long term equitypref paid-in comprehens stockhold liabil stockhold biogen inc
